License and Collaboration Agreements - Additional Information (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 23, 2022	May 04, 2022	Mar. 31, 2022	Jan. 10, 2021	Jul. 31, 2020
License
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized				$ 25,000,000.0
Zai Repotrectinib Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront cash payment received											$ 25,000,000.0
Total transaction price allocated to performance obligation	$ 25,700,000				$ 25,700,000
Zai Repotrectinib Agreement | Clinical Supply
Research And Development Arrangement Contract To Perform For Others [Line Items]
Total transaction price allocated to performance obligation	700,000				700,000
Revenue recognized	0	$ 200,000			400,000	$ 400,000
Zai Repotrectinib Agreement | Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments eligible to receive											151,000,000.0
Zai Repotrectinib Agreement | Development Milestones [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized		5,000,000.0
Zai Repotrectinib Agreement | Development Milestones [Member] | Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments eligible to receive											46,000,000.0
Zai Repotrectinib Agreement | Sales Milestones | Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments eligible to receive											$ 105,000,000.0
Zai Elzovantinib Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront cash payment received			$ 25,000,000.0
Total transaction price allocated to performance obligation									$ 25,900,000
Zai Elzovantinib Agreement [Member] | License
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized			$ 25,000,000.0
Zai Elzovantinib Agreement [Member] | Clinical Supply
Research And Development Arrangement Contract To Perform For Others [Line Items]
Total transaction price allocated to performance obligation									$ 900,000
Revenue recognized	100,000	$ 0			100,000	$ 0
Zai Elzovantinib Agreement [Member] | Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments eligible to receive										$ 336,000,000.0
Zai Elzovantinib Agreement [Member] | Development Milestones [Member] | Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments eligible to receive										121,000,000.0
Zai Elzovantinib Agreement [Member] | Sales Milestones | Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments eligible to receive										$ 215,000,000.0
LaNova License Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront cash payment received	25,000,000.0				25,000,000.0
LaNova License Agreement [Member] | Development Milestones [Member] | Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments eligible to receive								$ 195,000,000.0
LaNova License Agreement [Member] | Sales Milestones | Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments eligible to receive								$ 880,000,000.0
MD Anderson Collaboration Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Collaboration agreement total fund provided	$ 0				$ 0		$ 10,000,000.0
Collaboration Agreement Periodic Payment							$ 1,000,000.0